<DOC>
	<DOCNO>NCT00612456</DOCNO>
	<brief_summary>This 28 day study evaluate pharmacodynamic effect pazopanib eye drop central retinal thickness AMD patient</brief_summary>
	<brief_title>To Evaluate Pharmacodynamics , Safety , Pharmacokinetics Pazopanib Drops Adult Subjects With Neovascular AMD</brief_title>
	<detailed_description>Pazopanib formulate eye drop topical treatment age-related macular degeneration ( AMD ) . Safety , tolerability pharmacokinetics evaluate first study conduct healthy volunteer ( MD7108238 ) . In present study , three dose regimen pazopanib eye drop , administer 28 day , evaluated subject occult minimally classic subtypes choroidal neovascularization due AMD . This study design measure pharmacological activity topically administer pazopanib target tissue ( choroid retina ) patient AMD weekly evaluation central retinal thickness measure optical coherence tomography ( OCT ) . Evaluation efficacy perform exploratory basis weekly measurement visual acuity . The ocular systemic safety systemic pharmacokinetics pazopanib treatment 28 day also evaluate .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Agerelated macular degeneration patient diagnose subfoveal choroidal neovascularization study eye , follow characteristic require : central subfield thickness &gt; 300 micron investigatordetermined OCT ( inclusive subretinal fluid ) active subfoveal leakage determine investigatordetermined fluorescein angiography minimally classic occult classic CNV lesion lesion size great 12 disc area CNV &gt; 50 % lesion area &lt; 50 % lesion area blood = 25 % lesion area fibrosis Bestcorrected ETDRS visual acuity study eye 80 24 letter inclusive ( approximately 20/25 20/320 4/5 4/63 ) screen Female subject must nonchildbearing potential . Additional eye disease study eye could compromise best correct visual acuity ( i.e . glaucoma document visual field loss , clinically significant diabetic retinopathy , ischemic optic neuropathy , retinitis pigmentosa ) . CNV study eye due cause unrelated agerelated macular degeneration . The presence retinal angiomatous proliferation ( RAP ) study eye , determine investigator ( confirmation indocyanine green angiography require ) . Geographic atrophy involve center fovea study eye . Anterior segment vitreous abnormality study eye would preclude adequate observation fundus photograph , fluorescein angiography OCT. Vitreous , subretinal retinal hemorrhage study eye unrelated AMD . More one prior photodynamic therapy ( PDT ) treatment study eye . PDT treatment study eye &lt; 12 week prior dose . Previous treatment study eye ranibizumab ( Lucentis ) bevacizumab ( Avastin ) without resolution exudation ( intraretinal subretinal fluid document OCT ) . Use treatment , either approve experimental , AMD study eye within 60 day first dose investigational product . Intraocular surgery study eye within 3 month dose . Aphakia total absence posterior capsule ( Yttrium aluminum garnet ( YAG ) capsulotomy permit ) study eye . History vitrectomy study eye . Use topical ocular medication study eye within 7 day first dose investigational product expect use topical ocular medication treatment period , exception artificial tear ( refer Section 9.1 ) Active treatment fellow eye , exception preservativefree artificial tear . Current use medication know toxic retina , lens optic nerve ( e.g . desferoximine , chloroquine/hydrochloroquine , chlorpromazine , phenothiazine , tamoxifen , nicotinic acid , ethambutol ) . Use systemic steroid ( &gt; 10 mg prednisone equivalent/day ) within 14 day first dose . An unwillingness refrain wear contact lenses start screen visit , followup visit Medical history condition : Uncontrolled Diabetes Mellitus , hemoglobin A1c ( HbA1c ) &gt; 10 % . Myocardial infarction stroke within 12 month screen . Active bleeding disorder . Major surgery within 1 month screening . Hepatic impairment . Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>angiogenesis</keyword>
	<keyword>pazopanib ,</keyword>
	<keyword>age-related macular degeneration ( AMD ) ,</keyword>
	<keyword>vascular endothelial growth factor ( VEGF ) ,</keyword>
	<keyword>choroidal neovascularization ( CNV ) ,</keyword>
</DOC>